Hierdie inligting is slegs vir opvoedkundige doeleindes. Dit is nie bedoel as mediese advies nie. Raadpleeg altyd 'n gekwalifiseerde gesondheidsorgpraktisyn.
Beskrywing, Dosering, Newe-effekte, Kontra-indikasies. Data from EMA, URPL, openFDA and other regulatory sources.
| Salbutamol | Salmeterol | |
|---|---|---|
| Aktiewe bestanddele | Salbutamolum | Salmeterolum + Fluticasoni propionas |
| ATC-kode | R03CC02 | R03AK06 |
| Vorm | Tabletki | Proszek do inhalacji, podzielony |
| Dosering | 4 mg | (50 mikrogramów + 250 mikrogramów)/dawkę |
| Toedieningsweg | doustna | wziewna |
| Vervaardiger | Zakłady Farmaceutyczne POLPHARMA S.A. | InPharm Sp. z o.o. |
Salbutamol (INN: Salbutamolum, ATC R03CC02) and Salmeterol (INN: Salmeterolum + Fluticasoni propionas, ATC R03AK06) differ in active substance, indications, and safety profile. The table above summarizes the clinical differences from regulatory documents.
Combination safety depends on mechanisms and your health profile. Use our interactions checker and always consult your doctor or pharmacist before combining medications.
Both drugs are approved when used per label. Safety is patient-specific — the better choice depends on your condition, other medications, allergies, and comorbidities. Consult a healthcare professional for personalized advice.
Hierdie inligting is slegs vir opvoedkundige doeleindes. Dit is nie bedoel as mediese advies nie. Raadpleeg altyd 'n gekwalifiseerde gesondheidsorgpraktisyn.